PARAGARD T 380A Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Paragard T 380a, and when can generic versions of Paragard T 380a launch?
Paragard T 380a is a drug marketed by Coopersurgical and is included in one NDA.
The generic ingredient in PARAGARD T 380A is copper. There are fifteen drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the copper profile page.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for PARAGARD T 380A?
- What are the global sales for PARAGARD T 380A?
- What is Average Wholesale Price for PARAGARD T 380A?
Summary for PARAGARD T 380A
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 2869 |
Clinical Trials: | 13 |
Patent Applications: | 2,017 |
What excipients (inactive ingredients) are in PARAGARD T 380A? | PARAGARD T 380A excipients list |
DailyMed Link: | PARAGARD T 380A at DailyMed |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for PARAGARD T 380A
Generic Entry Date for PARAGARD T 380A*:
Constraining patent/regulatory exclusivity:
NEW INSERTER INTENDED TO FACILITATE SINGLE-HAND PLACEMENT NDA:
Dosage:
SYSTEM;INTRAUTERINE |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Recent Clinical Trials for PARAGARD T 380A
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Kenya Medical Research Institute | Phase 4 |
Eastern Virginia Medical School | Phase 4 |
CONRAD | Phase 4 |
Pharmacology for PARAGARD T 380A
Drug Class | Copper-containing Intrauterine Device |
Physiological Effect | Decreased Embryonic Implantation Decreased Sperm Motility Inhibit Ovum Fertilization |
US Patents and Regulatory Information for PARAGARD T 380A
PARAGARD T 380A is protected by zero US patents and one FDA Regulatory Exclusivity.
Based on analysis by DrugPatentWatch, the earliest date for a generic version of PARAGARD T 380A is ⤷ Sign Up.
This potential generic entry date is based on NEW INSERTER INTENDED TO FACILITATE SINGLE-HAND PLACEMENT.
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
FDA Regulatory Exclusivity protecting PARAGARD T 380A
NEW INSERTER INTENDED TO FACILITATE SINGLE-HAND PLACEMENT
Exclusivity Expiration: ⤷ Sign Up
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Coopersurgical | PARAGARD T 380A | copper | SYSTEM;INTRAUTERINE | 018680-001 | Nov 15, 1984 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |